Related Experiment Video

Updated: Dec 25, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.4K

INTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without)

Richard J Benjamin1, Laurence Corash1, Philip J Norris2,3

  • 1Cerus Corporation, Concord, California.

Transfusion
|April 5, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K
A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting07:27

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting

Published on: May 16, 2013

19.0K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
967
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
83.0K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
83.0K